Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Pacira Pharma (PCRX) Tops Q3 Views
November 2, 2016 7:35 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.22, $0.24 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $67.16 million.
2016 Outlook
Pacira updates its full year 2016 financial guidance as follows:
EXPAREL net product sales of $263... More